CTLA4 and hepatocellular carcinoma: For example, combination of histone deacetylase inhibitor belinostat with anti-CTLA-4, or combination of anti-CTLA-4 plus anti-PD-1 antibodies could lead to complete tumor rejection in a mouse HCC model [158].